Skip to content
1887

Access Microbiology open research platform logo Access Microbiology

Volume 6, Issue 10

Genetic diversity and genomic epidemiology of SARS-CoV-2 during the first 3 years of the pandemic in Morocco: comprehensive sequence analysis, including the unique lineage B.1.528 in Morocco Open Access

Abstract

During the 3 years following the emergence of the COVID-19 pandemic, the African continent, like other regions of the world, was substantially impacted by COVID-19. In Morocco, the COVID-19 pandemic has been marked by the emergence and spread of several SARS-CoV-2 variants, leading to a substantial increase in the incidence of infections and deaths. Nevertheless, the comprehensive understanding of the genetic diversity, evolution, and epidemiology of several viral lineages remained limited in Morocco. This study sought to deepen the understanding of the genomic epidemiology of SARS-CoV-2 through a retrospective analysis. The main objective of this study was to analyse the genetic diversity of SARS-CoV-2 and identify distinct lineages, as well as assess their evolution during the pandemic in Morocco, using genomic epidemiology approaches. Furthermore, several key mutations in the functional proteins across different viral lineages were highlighted along with an analysis of the genetic relationships amongst these strains to better understand their evolutionary pathways. A total of 2274 genomic sequences of SARS-CoV-2 isolated in Morocco during the period of 2020 to 2023, were extracted from the GISAID EpiCoV database and subjected to analysis. Lineages and clades were classified according to the nomenclature of GISAID, Nextstrain, and Pangolin. The study was conducted and reported in accordance with STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. An exhaustive analysis of 2274 genomic sequences led to the identification of 157 PANGO lineages, including notable lineages such as B.1, B.1.1, B.1.528, and B.1.177, as well as variants such as B.1.1.7, B.1.621, B.1.525, B.1.351, B.1.617.1, B.1.617.2, and its notable sublineages AY.33, AY.72, AY.112, AY.121 that evolved over time before being supplanted by Omicron in December 2021. Among the 2274 sequences analysed, Omicron and its subvariants had a prevalence of 59.5%. The most predominant clades were 21K, 21L, and 22B, which are respectively related phylogenetically to BA.1, BA.2, and BA.5. In June 2022, Morocco rapidly observed a recrudescence of cases of infection, with the emergence and concurrent coexistence of subvariants from clade 22B such as BA.5.2.20, BA.5, BA.5.1, BA.5.2.1, and BF.5, supplanting the subvariants BA.1 (clade display 21K) and BA.2 (clade display 21L), which became marginal. However, XBB (clade 22F) and its progeny such XBB.1.5(23A), XBB.1.16(23B), CH.1.1(23C), XBB.1.9(23D), XBB.2.3(23E), EG.5.1(23F), and XBB.1.5.70(23G) have evolved sporadically. Furthermore, several notable mutations, such as H69del/V70del, G142D, K417N, T478K, E484K, E484A, L452R, F486P, N501Y, Q613H, D614G, and P681H/R, have been identified. Some of these SARS-CoV-2 mutations are known to be involved in increasing transmissibility, virulence, and antibody escape. This study has identified several distinct lineages and mutations involved in the genetic diversity of Moroccan isolates, as well as the analysis of their evolutionary trends. These findings provide a robust basis for better understanding the distinct mutations and their roles in the variation of transmissibility, pathogenicity, and antigenicity (immune evasion/reinfection). Furthermore, the noteworthy number of distinct lineages identified in Morocco highlights the importance of maintaining continuous surveillance of COVID-19. Moreover, expanding vaccination coverage would also help protect patients against more severe clinical disease.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): genetic diversity , genomic sequence , lineage , omicron , SARS-CoV-2 and variant
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. The Microbiology Society waived the open access fees for this article.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000853.v4
2024-10-07
2026-04-20

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/acmi/6/10/acmi000853.v4.html?itemId=/content/journal/acmi/10.1099/acmi.0.000853.v4&mimeType=html&fmt=ahah

References

  1. Djorwe S, Malki A, Nzoyikorera N, Nyandwi J, Zebsoubo SP et al. Genetic diversity and genomic epidemiology of SARS-cov-2 during the first three years of the pandemic in Morocco: comprehensive sequence analysis, including the unique lineage B.1.528 in Morocco. figshare 2024
     [Google Scholar]
  2. Zhang Y, Belayachi J, Yang Y, Fu Q, Rodewald L et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health 2022; 22:1584 [View Article] [PubMed]
     [Google Scholar]
  3. WHO Weekly epidemiological update on COVID-19; 2019 https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-august-2023 accessed 10 August 2023
  4. Najimi N, Tajount L, Regragui Z, Remz C, Ait-Lhaj-Mhand R et al. Pre-pandemic antibodies screening against SARS-CoV-2 and virus detection among children diagnosed with eruptive fevers. Int J Immunopathol Pharmacol 2024; 38:3946320241260633 [View Article] [PubMed]
     [Google Scholar]
  5. Voskarides K. SARS-CoV-2: tracing the origin, tracking the evolution. BMC Med Genom 2022; 15:62 [View Article] [PubMed]
     [Google Scholar]
  6. Yu M, Li J, Gao W, Li Z, Zhang W. Multiple E3 ligases act as antiviral factors against SARS-CoV-2 via inducing the ubiquitination and degradation of ORF9b. J Virol 2024; 98:e0162423 [View Article] [PubMed]
     [Google Scholar]
  7. Al-Qaaneh AM, Alshammari T, Aldahhan R, Aldossary H, Alkhalifah ZA et al. Genome composition and genetic characterization of SARS-CoV-2. Saudi J Biol Sci 2021; 28:1978–1989 [View Article] [PubMed]
     [Google Scholar]
  8. Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol 2022; 94:1738–1744 [View Article] [PubMed]
     [Google Scholar]
  9. Chouikha A, Fares W, Laamari A, Haddad-Boubaker S, Belaiba Z et al. Molecular epidemiology of SARS-CoV-2 in Tunisia (North Africa) through several successive waves of COVID-19. Viruses 2022; 14:624 [View Article] [PubMed]
     [Google Scholar]
  10. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453–1457 [View Article]
     [Google Scholar]
  11. Khare S, Gurry C, Freitas L, Schultz MB, Bach G et al. GISAID’s role in pandemic response. China CDC Wkly 2021; 3:1049–1051 [View Article] [PubMed]
     [Google Scholar]
  12. Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 2020; 5:1403–1407 [View Article] [PubMed]
     [Google Scholar]
  13. O’Toole Á, Scher E, Underwood A, Jackson B, Hill V et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol 2021; 7:veab064 [View Article] [PubMed]
     [Google Scholar]
  14. Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment, mutation calling and quality control for viral genomes. JOSS 2021; 6:3773 [View Article]
     [Google Scholar]
  15. Fernandes JD, Hinrichs AS, Clawson H, Gonzalez JN, Lee BT et al. The UCSC SARS-CoV-2 genome browser. Nat Genet 2020; 52:991–998 [View Article] [PubMed]
     [Google Scholar]
  16. Mercatelli D, Giorgi FM. Geographic and genomic distribution of SARS-CoV-2 mutations. Front Microbiol 2020; 11:1800 [View Article] [PubMed]
     [Google Scholar]
  17. Lina B. Les différentes phases de l’évolution moléculaire et antigénique des virus SARS-CoV-2 au cours des 20 mois suivant son émergence. Bulletin de l’Académie Nationale de Médecine 2022; 206:87–99 [View Article]
     [Google Scholar]
  18. Wang Q, Guo Y, Iketani S, Nair MS, Li Z et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022; 608:603–608 [View Article] [PubMed]
     [Google Scholar]
  19. Ghosh N, Nandi S, Saha I. A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein. Int Immunopharmacol 2022; 105:108565 [View Article] [PubMed]
     [Google Scholar]
  20. Nazario-Toole AE, Xia H, Gibbons TF. Whole-genome sequencing of SARS-CoV-2: using phylogeny and structural modeling to contextualize local viral evolution. Mil Med 2022; 187:e130–e137 [View Article] [PubMed]
     [Google Scholar]
  21. Gonçalves RL, Leite TCR, Dias B de P, Caetano CC da S, de Souza ACG et al. SARS-CoV-2 mutations and where to find them: an in silico perspective of structural changes and antigenicity of the spike protein. J Biomol Struct Dyn 2022; 40:3336–3346 [View Article] [PubMed]
     [Google Scholar]
  22. Li Q, Wu J, Nie J, Zhang L, Hao H et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 2020; 182:1284–1294 [View Article] [PubMed]
     [Google Scholar]
  23. Odongo S, Okella H, Ndekezi C, Okee M, Namayanja M et al. Towards refinement of COVID-19 disease vaccines, diagnostics, and therapeutics. PLoS One 2021; 17:e0279428 [View Article] [PubMed]
     [Google Scholar]
  24. Yi H, Wang J, Wang J, Lu Y, Zhang Y et al. The emergence and spread of novel SARS-CoV-2 variants. Front Public Health 2021; 9:696664 [View Article] [PubMed]
     [Google Scholar]
  25. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 2021; 22:757–773 [View Article] [PubMed]
     [Google Scholar]
  26. Hamzaoui Z, Ferjani S, Medini I, Charaa L, Landolsi I et al. Genomic surveillance of SARS-CoV-2 in North Africa: 4 years of GISAID data sharing. IJID Reg 2024; 11:100356 [View Article] [PubMed]
     [Google Scholar]
  27. Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 2021; 184:2348–2361 [View Article] [PubMed]
     [Google Scholar]
  28. Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L et al. Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern: a retrospective cohort study comparing B.1.1.7 (alpha), B.1.351 (beta), and B.1.617.2 (delta). Clin Infect Dis 2022; 75:e1128–e1136 [View Article] [PubMed]
     [Google Scholar]
  29. Basheer A, Zahoor I. Genomic epidemiology of SARS-CoV-2 divulge B.1, B.1.36, and B.1.1.7 as the most dominant lineages in first, second, and third wave of SARS-CoV-2 infections in Pakistan. Microorganisms 2021; 9:2609 [View Article] [PubMed]
     [Google Scholar]
  30. Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Usme-Ciro JA et al. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infect Genet Evol 2021; 95:105038 [View Article] [PubMed]
     [Google Scholar]
  31. Chatterjee D, Tauzin A, Laumaea A, Gong SY, Bo Y et al. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. Viruses 2022; 14:144 [View Article] [PubMed]
     [Google Scholar]
  32. McCallum M, De Marco A, Lempp FA, Tortorici MA, Pinto D et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 2021; 184:2332–2347 [View Article] [PubMed]
     [Google Scholar]
  33. Wang P, Nair MS, Liu L, Iketani S, Luo Y et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021; 593:130–135 [View Article] [PubMed]
     [Google Scholar]
  34. Cerutti G, Guo Y, Zhou T, Gorman J, Lee M et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 2021; 29:819–833 [View Article] [PubMed]
     [Google Scholar]
  35. Morang’a CM, Ngoi JM, Gyamfi J, Amuzu DSY, Nuertey BD et al. Genetic diversity of SARS-CoV-2 infections in Ghana from 2020-2021. Nat Commun 2022; 13:2494 [View Article] [PubMed]
     [Google Scholar]
  36. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021; 596:276–280 [View Article] [PubMed]
     [Google Scholar]
  37. Alkhatib M, Svicher V, Salpini R, Ambrosio FA, Bellocchi MC et al. SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021. Microbiol Spectr 2021; 9:e0109621 [View Article] [PubMed]
     [Google Scholar]
  38. Hemlali M, Chouati T, Ghammaz H, Melloul M, Alaoui Amine S et al. Coding-complete genome sequences of a delta subvariant (AY.33) of SARS-CoV-2 obtained from Moroccan COVID-19 patients. Microbiol Resour Announc 2022; 11:e0109921 [View Article] [PubMed]
     [Google Scholar]
  39. Sahni C, Chowdhury PBR, Devadas D, Ashish A, Singh NK et al. SARS-CoV-2 mutations responsible for immune evasion leading to breakthrough infection. Cureus; 2022 https://www.cureus.com/articles/114827-sars-cov-2-mutations-responsible-for-immune-evasion-leading-to-breakthrough-infection accessed 15 February 2024
  40. Balupuri A, Kim J-M, Choi K-E, No JS, Kim I-H et al. Comparative computational analysis of spike protein structural stability in SARS-CoV-2 Omicron subvariants. Int J Mol Sci 2023; 24:16069 [View Article] [PubMed]
     [Google Scholar]
  41. Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol 2022; 32:e2381 [View Article] [PubMed]
     [Google Scholar]
  42. Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 2022; 185:2422–2433 [View Article] [PubMed]
     [Google Scholar]
  43. Yu J, Collier A-RY, Rowe M, Mardas F, Ventura JD et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. N Engl J Med 2022; 386:1579–1580 [View Article] [PubMed]
     [Google Scholar]
  44. Huang S-H, Chen Y-T, Lin X-Y, Ly Y-Y, Lien S-T et al. In silico prediction of immune-escaping hot spots for future COVID-19 vaccine design. Sci Rep 2023; 13:13468 [View Article] [PubMed]
     [Google Scholar]
  45. Habib MT, Rahman S, Afrad MH, Howlader AM, Khan MH et al. Natural selection shapes the evolution of SARS-CoV-2 Omicron in Bangladesh. Front Genet 2023; 14:1220906 [View Article] [PubMed]
     [Google Scholar]
  46. Thakur S, Sasi S, Pillai SG, Nag A, Shukla D et al. SARS-CoV-2 mutations and their impact on diagnostics, therapeutics and vaccines. Front Med 2022; 9:815389 [View Article] [PubMed]
     [Google Scholar]
  47. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol 2023; 21:162–177 [View Article] [PubMed]
     [Google Scholar]
  48. Cao Y, Yisimayi A, Jian F, Song W, Xiao T et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022; 608:593–602 [View Article] [PubMed]
     [Google Scholar]
  49. Sarkar A, Omar S, Alshareef A, Fanous K, Sarker S et al. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: a systematic review. Hum Vaccin Immunother 2023; 19:2212568 [View Article] [PubMed]
     [Google Scholar]
  50. Tamura T, Ito J, Uriu K, Zahradnik J, Kida I et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun 2023; 14:2800 [View Article] [PubMed]
     [Google Scholar]
  51. Ito J, Suzuki R, Uriu K, Itakura Y, Zahradnik J et al. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Nat Commun 2023; 14:2671 [View Article] [PubMed]
     [Google Scholar]
  52. Makowski EK, Schardt JS, Smith MD, Tessier PM. Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape. PLoS Comput Biol 2022; 18:e1010160 [View Article] [PubMed]
     [Google Scholar]
  53. Aguilar Ticona JP, Xiao M, Li D, Nery N Jr, Hitchings M et al. Extensive transmission of SARS-CoV-2 BQ.1* variant in A population with high levels of hybrid immunity: a prevalence survey. Int J Infect Dis 2024; 139:159–167 [View Article] [PubMed]
     [Google Scholar]
  54. Liu Z, Li J, Pei S, Lu Y, Li C et al. An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants. Front Cell Infect Microbiol 2023; 13:1297078 [View Article] [PubMed]
     [Google Scholar]
  55. Giancotti R, Lomoio U, Puccio B, Tradigo G, Vizza P et al. The Omicron XBB.1 variant and its descendants: genomic mutations, rapid dissemination and notable characteristics. Biology 2024; 13:90 [View Article] [PubMed]
     [Google Scholar]
  56. WHO Tracking SARS-CoV-2 variants; 2024 https://www.who.int/activities/tracking-SARS-CoV-2-variants accessed 8 March 2024
  57. Cobar O, Cobar S. XBB.2.3, prevalence, structural, genomic, and pathogenic properties. Med Res Arch; 2023 https://esmed.org/MRA/mra/article/view/4137 accessed 1 April 2024
  58. Wu H, Xing N, Meng K, Fu B, Xue W et al. Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host Microbe 2021; 29:1788–1801 [View Article] [PubMed]
     [Google Scholar]
  59. Muradyan N, Arakelov V, Sargsyan A, Paronyan A, Arakelov G et al. Impact of mutations on the stability of SARS-CoV-2 nucleocapsid protein structure. Sci Rep 2024; 14:5870 [View Article] [PubMed]
     [Google Scholar]
  60. Ahmad W, Ahmad S, Basha R. Analysis of the mutation dynamics of SARS-CoV-2 genome in the samples from Georgia State of the United States. Gene 2022; 841:146774 [View Article] [PubMed]
     [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000853.v4
Loading
Genetic diversity and genomic epidemiology of SARS-CoV-2 during the first 3 years of the pandemic in Morocco: comprehensive sequence analysis, including the unique lineage B.1.528 in Morocco
Access Microbiology 6, 000853.v4 (2024); https://doi.org/10.1099/acmi.0.000853.v4
/content/journal/acmi/10.1099/acmi.0.000853.v4
/content/journal/acmi/10.1099/acmi.0.000853.v4
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error